BioWorld

July 7, 2009

View Archived Issues

Ikaria, BioLineRx Enter Cardiac Licensing Deal Worth $282.5M

Ikaria Holdings Inc. has entered a deal worth a potential $282.5 million with Jerusalem-based BioLineRx Ltd. to license a cardiac remodeling product. (BioWorld Today) Read More

OxiGene Frees up Cash, Product Rights in Low-Priced JV Buyout

Read More

Spectrum Spirals on Zevalin Complete Response Letter

Read More

FDA Query Gives Confidence to Protalix for Gaucher Drug

Read More

Novacta Gets $21M Backing for Antibiotics Development

Read More

NIH Finalizes Embryonic Stem Cell Funding Guidelines

Read More

Other News To Note

Read More

Clinic Roundup

Read More